Can three drugs together shrink Hard-to-Treat breast tumors?

This phase II trial is testing whether a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and fulvestrant (a hormone blocker)—can slow or stop the growth of a specific type of advanced breast cancer. The study enrolls people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed surgically, and whose tumors have certain genetic changes (such as BRCA mutations) that may make them sensitive to olaparib. Participants receive all three drugs on a regular schedule, and researchers track how long the cancer stays under control.